Business Context and Reporting Period
Company: Skye Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 22, 2024
Event: Special Meeting of Stockholders held to approve amendments to the Company's equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
The primary material change reported is the stockholder approval of the second amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan. Key changes include:
- Share Increase: The number of shares of Common Stock issuable under the plan was increased by 1,535,655.
- IS Option Cap: The number of incentive stock options that may be granted was increased to 4,000,000.
- Extension: The expiration date of the plan was extended to September 10, 2034.
- Renaming: The plan was renamed the "Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan."
- Features: The automatic share replenishment feature was retained.
Voting Results and Management Commentary
At the Special Meeting, holders of 23,686,215 shares were present, constituting a quorum. The voting results for the proposal to approve the Amended and Restated Plan were as follows:
| Vote Type | Number of Votes |
|---|---|
| For | 17,444,443 |
| Against | 6,228,672 |
| Abstentions | 13,100 |
The plan became effective immediately upon stockholder approval. The filing incorporates by reference the Definitive Proxy Statement filed on September 23, 2024, for a full description of the plan's material terms.
Investor Verification Checklist
- Verify the total number of shares authorized for issuance under the new plan limits.
- Review the full text of the Amended and Restated Omnibus Incentive Plan (Exhibit 10.1) for specific vesting schedules and eligibility criteria.
- Confirm the impact of the 1,535,655 share increase on potential future dilution.
- Check the September 23, 2024 Proxy Statement for detailed management rationale regarding the plan amendments.